Cytomegalovirus (CMV) Nursing Care Management

CMV is everywhere and usually silent in healthy people. The patients who get hurt are the immunocompromised: transplant recipients, HIV patients, and neonates. That is where CMV turns into retinitis, pneumonia, colitis, and organ disease. Know who is at risk, watch for reactivation, and protect them from added infection.

What is Cytomegalovirus?

CMV, also called Human Herpesvirus 5 (HHV-5), is a double-stranded DNA virus in the Herpesviridae family.

• It shares genome, virion structure, and the ability to cause latent and persistent infection with other herpes viruses.
• At least 60% of the US population has been exposed to CMV, with prevalence above 90% in high-risk groups (such as men who have sex with men).
• CMV usually causes an asymptomatic infection, then stays latent for life and may reactivate.
• In immunocompromised patients, symptomatic disease can hit almost any organ: fever of unknown origin, pneumonia, hepatitis, encephalitis, myelitis, colitis, uveitis, retinitis, and neuropathy.

Pathophysiology

CMV is a lytic virus that causes a cytopathic effect in vitro and in vivo.

• Once the host is infected, CMV DNA can be detected by PCR across all cell lineages and organ systems.
• It first infects the epithelial cells of the salivary gland, producing persistent infection and viral shedding.
• Genitourinary infection leads to clinically inconsequential viruria.
• Despite ongoing replication in the kidney, renal dysfunction is rare except in renal transplant recipients, where CMV is linked to rare glomerulopathy and possible graft rejection.

Statistics and Incidences

In the United States, nearly one in three children are infected with CMV by age 5.

• In developing countries most infections are acquired in childhood; in developed countries up to 50% of young adults are CMV seronegative.
• Seropositivity rises with age. A US study reported an increase from 36% in children aged 6-11 years to 91% in people older than 80 years.
• Other factors include ethnicity (77% in Mexican Americans, 71% in Black Americans), female sex, foreign-born status, and low socioeconomic status.
• Depending on the population, CMV is found in 40%-100% of people.

Causes

• Contact with fluids. CMV mainly spreads through fluids that contain the virus: saliva, urine, semen, cervical mucus, blood, breastmilk.
• Blood transfusion. Multiple-unit transfusion is a risk factor for CMV mononucleosis and has been implicated in postoperative or post-trauma fever.
• Increased hospital stay. CMV frequently reactivates in critically ill patients and is linked to longer hospital and ICU stays, longer mechanical ventilation, and higher morbidity and mortality.

Clinical Manifestations

In healthy people, infection can cause mild illness:

• Fever
• Sore throat
• Fatigue
• Headache
• Swollen glands
• Loss of appetite
• Muscle weakness

Assessment and Diagnostic Findings

Serologic tests for CMV antibodies (IgM and IgG) are widely available.

• ELISA. The most common serologic test for measuring CMV antibodies.
• PCR. The standard test for congenital CMV is PCR on saliva, with urine collected for confirmation.
• Antigen testing. The pp65 assay detects messenger matrix proteins on the virus by immunofluorescence or messenger RNA amplification; these proteins are expressed only during viral replication.
• Shell vial assay. The specimen is added to a vial containing a permissive cell line for CMV; as sensitive as traditional tissue culture.
• Cytopathology. Intracellular inclusions surrounded by a clear halo, shown with Giemsa, Wright, hematoxylin-eosin, or Papanicolaou stains.

Medical Management

No treatment is indicated for CMV in healthy people.

• Activity. Fatigue is the most common lingering symptom and may persist up to 18 months after primary infection, though usually much shorter; average recovery from fatigue is 1-2 months.
• Antiviral treatment. Used for immunocompromised patients with sight-threatening or life-threatening CMV disease.
• Prevention. Ganciclovir is used for prophylactic or preemptive treatment of CMV disease in transplant recipients.
• Outpatient care. When ganciclovir is given outpatient for CMV retinitis, follow up with a CBC once per week to monitor for hematologic toxicity; check electrolytes at the same time.
• Inpatient care. Keep patients well hydrated; nutrition matters because many are debilitated by transplant or HIV disease; guard against iatrogenic infection.

Pharmacologic Management

The goals are to prevent disease outbreaks and complications and reduce morbidity.

• Antivirals. CMV is a double-stranded DNA virus; antivirals target viral DNA polymerase, slow DNA replication, and may interfere with virion maturation.
• Immune globulin. Immunoglobulin pooled from the serum of immunized donors.
• Antimetabolite. Inhibits cell growth and proliferation.

Nursing Management

Nursing Assessment

• History. Varies by whether the host is immunocompetent or immunocompromised. Many infected people show no symptoms.
• Physical exam. Most patients have few clinical findings.

Nursing Diagnosis

• Risk for infection as evidenced by fatigue, sore throat, mild headache.
• Hyperthermia related to increased metabolic demand.
• Impaired swallowing related to throat swelling.
• Fatigue related to poor physical state.

Nursing Care Planning and Goals

• Remain free of infection, with normal vital signs and no signs of infection.
• Maintain body temperature below 39° C (102.2° F).
• Swallow safely, with no aspiration, coughing, choking, or food stasis.
• Set priorities so essential tasks come before nonessential ones during periods of fatigue.

Nursing Intervention

• Prevent infection. Wash hands and teach the patient and family to wash hands before contact and between procedures; encourage fluid intake of 2,000 to 3,000 mL per day unless contraindicated; if infection occurs, give the full course of antibiotics as prescribed, even if symptoms improve.
• Manage hyperthermia. Remove excess clothing and covers; give antipyretics as prescribed; adjust cooling measures to the patient's response; start IV normal saline as indicated.
• Improve swallowing. Feed slowly in small amounts; alternate liquids and solids when possible; keep the patient upright for 30 to 45 minutes after a meal.
• Reduce fatigue. Assess severity, changes over time, and aggravating or relieving factors; limit environmental stimuli during planned rest and sleep; help the patient set priorities; support adequate nutrition; teach energy conservation (sitting for ADLs, dividing them into segments) and the signs of overexertion.

Evaluation

Goals are met when the patient stays free of infection with normal vitals, holds temperature below 39° C (102.2° F), swallows safely without aspiration, and prioritizes essential tasks during fatigue.

Documentation

• Individual findings: factors affecting the patient, interactions, social exchanges, specifics of behavior.
• Cultural and religious beliefs and expectations.
• Plan of care.
• Teaching plan.
• Responses to interventions, teaching, and actions performed.
• Attainment or progress toward desired outcomes.